Samarth Kulkarni - 18 Feb 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Michael Esposito, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
18 Feb 2022
Transactions value $
$0
Form type
4
Filing time
22 Feb 2022, 16:43:16 UTC
Previous filing
22 Dec 2021
Next filing
14 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +115K $0.00 115K 18 Feb 2022 Common Shares 115K $58.29 Direct F1
transaction CRSP Restricted Stock Units Award $0 +53K $0.00 53K 18 Feb 2022 Common Shares 53K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 18, 2022 with respect to 115,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.